MedPath

Technetium Tc-99m sestamibi

Generic Name
Technetium Tc-99m sestamibi
Brand Names
Cardiolite
Drug Type
Small Molecule
Chemical Formula
C36H66N6O6Tc
CAS Number
109581-73-9
Unique Ingredient Identifier
971Z4W1S09

Overview

Technetium Tc-99m sestamibi (commonly sestamibi) is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands, hence the name sesta (6) MIBI.. Following intravenous injection of the drug, Technetium Tc-99m sestamibi is taken up by the myocardium, parathyroid, and/or breast tissue. The mechanism by which sestamibi localizes to these tissues has not been established. Single photon emission computed tomography (SPECT) is then performed to detect the gamma ray emmitted by the decay of Technetium-99m to Technetium-99. Currently available within a preparation kit for injection, Technetium Tc 99m Sestamibi is indicated for: 1) detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects); and 2) evaluating myocardial function and developing information for use in patient management decisions.

Background

Technetium Tc-99m sestamibi (commonly sestamibi) is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands, hence the name sesta (6) MIBI.. Following intravenous injection of the drug, Technetium Tc-99m sestamibi is taken up by the myocardium, parathyroid, and/or breast tissue. The mechanism by which sestamibi localizes to these tissues has not been established. Single photon emission computed tomography (SPECT) is then performed to detect the gamma ray emmitted by the decay of Technetium-99m to Technetium-99. Currently available within a preparation kit for injection, Technetium Tc 99m Sestamibi is indicated for: 1) detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects); and 2) evaluating myocardial function and developing information for use in patient management decisions.

Indication

Technetium Tc 99m Sestamibi is indicated for: 1) detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects); and 2) evaluating myocardial function and developing information for use in patient management decisions.

Associated Conditions

  • Coronary Artery Disease (CAD)

FDA Approved Products

TECHNETIUM TC 99M SESTAMIBI
Manufacturer:Jubilant Draximage (USA) Inc.
Route:INTRAVENOUS
Strength:1 mg in 1 mL
Approved: 2017/08/13
NDC:45548-141
Kit for the Preparation of Technetium Tc99m Sestamibi
Manufacturer:Sun Pharmaceutical Industries, Inc.
Route:INTRAVENOUS
Strength:1 mg in 10 mL
Approved: 2020/03/31
NDC:45567-0555
Kit for the Preparation of Technetium Tc99m Sestamibi
Manufacturer:Cardinal Health 414, LLC
Route:PARENTERAL
Strength:1 mg in 5 mL
Approved: 2017/11/16
NDC:65857-500

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath